Portolan Capital Management LLC Purchases 8,686 Shares of Bio-Rad Laboratories, Inc. (NYSE:BIO)

Portolan Capital Management LLC grew its position in Bio-Rad Laboratories, Inc. (NYSE:BIO - Free Report) by 39.7% in the 4th quarter, according to its most recent disclosure with the SEC. The fund owned 30,586 shares of the medical research company's stock after buying an additional 8,686 shares during the period. Portolan Capital Management LLC owned approximately 0.11% of Bio-Rad Laboratories worth $10,048,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also recently made changes to their positions in the company. Wealthfront Advisers LLC bought a new stake in shares of Bio-Rad Laboratories in the 4th quarter worth $342,686,000. Norges Bank bought a new position in Bio-Rad Laboratories during the 4th quarter valued at about $41,644,000. Wedge Capital Management L L P NC purchased a new stake in shares of Bio-Rad Laboratories during the 4th quarter valued at about $28,740,000. Mawer Investment Management Ltd. grew its stake in shares of Bio-Rad Laboratories by 17.9% in the fourth quarter. Mawer Investment Management Ltd. now owns 256,927 shares of the medical research company's stock worth $84,403,000 after acquiring an additional 39,042 shares during the period. Finally, Proficio Capital Partners LLC purchased a new position in shares of Bio-Rad Laboratories during the fourth quarter valued at approximately $9,820,000. Institutional investors own 65.24% of the company's stock.

Bio-Rad Laboratories Price Performance

BIO stock traded down $7.19 during midday trading on Friday, hitting $238.02. The company's stock had a trading volume of 231,477 shares, compared to its average volume of 319,120. The firm has a market capitalization of $6.67 billion, a price-to-earnings ratio of -3.66 and a beta of 1.12. The company has a quick ratio of 4.85, a current ratio of 6.48 and a debt-to-equity ratio of 0.18. Bio-Rad Laboratories, Inc. has a 12 month low of $215.38 and a 12 month high of $387.99. The company has a 50 day moving average of $255.62 and a two-hundred day moving average of $311.81.

Bio-Rad Laboratories (NYSE:BIO - Get Free Report) last posted its quarterly earnings data on Thursday, February 13th. The medical research company reported $2.90 earnings per share for the quarter, beating analysts' consensus estimates of $2.86 by $0.04. Bio-Rad Laboratories had a negative net margin of 71.86% and a positive return on equity of 3.90%. On average, analysts expect that Bio-Rad Laboratories, Inc. will post 10.81 EPS for the current year.

Wall Street Analyst Weigh In

A number of equities research analysts have weighed in on BIO shares. StockNews.com lowered shares of Bio-Rad Laboratories from a "buy" rating to a "hold" rating in a research note on Monday, February 17th. Royal Bank of Canada reiterated an "outperform" rating and set a $481.00 price objective on shares of Bio-Rad Laboratories in a research report on Tuesday, January 14th. Finally, Wells Fargo & Company cut their price target on Bio-Rad Laboratories from $320.00 to $270.00 and set an "equal weight" rating for the company in a research note on Thursday. Three research analysts have rated the stock with a hold rating and three have issued a buy rating to the company's stock. Based on data from MarketBeat, the company currently has a consensus rating of "Moderate Buy" and a consensus target price of $380.20.

Bio-Rad Laboratories Profile

Bio-Rad Laboratories, Inc manufactures and distributes life science research and clinical diagnostic products in the United States, Europe, Asia, Canada, and Latin America. It operates through two segments, Life Science and Clinical Diagnostics. The company develops, manufactures, and markets instruments, systems, reagents, and consumables to separate, purify, characterize, and quantitate biological materials such as cells, proteins, and nucleic acids for proteomics, genomics, biopharmaceutical production, cellular biology, and food safety markets.